TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Tyra Bioscience ( (TYRA) ).
Tyra Biosciences announced the appointment of Bhavesh Ashar as Chief Operating Officer, effective December 1, 2025, succeeding Daniel Bensen who will become the Chief Discovery Officer. Mr. Ashar brings extensive experience in oncology from his previous roles at SpringWorks Therapeutics, Bayer, and Sanofi Genzyme. His employment agreement includes a base salary of $550,000, stock options, and severance benefits, indicating a strategic move to strengthen the company’s executive team and potentially enhance its market position.
The most recent analyst rating on (TYRA) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.
Spark’s Take on TYRA Stock
According to Spark, TipRanks’ AI Analyst, TYRA is a Neutral.
Tyra Bioscience’s overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.
To see Spark’s full report on TYRA stock, click here.
More about Tyra Bioscience
Average Trading Volume: 296,254
Technical Sentiment Signal: Buy
Current Market Cap: $1.2B
Find detailed analytics on TYRA stock on TipRanks’ Stock Analysis page.